RCMI Coordinating Center (RCMI CC) Header Logo

Tarun Mandal

TitleMcCaffrey/Norwood Endowed Professor of Pharmacy
Faculty RankProfessor
InstitutionXavier University of Louisiana
AddressXavier University of Louisiana
1 Drexel Drive
New Orleans LA 70125
vCardDownload vCard
    Other Positions
    TitleAdjunct Professor of Pharmaceutics
    InstitutionUniversity of Louisiana at Monroe

    TitleAdjunct Professor of Pharmaceutics
    InstitutionUniversity of Tennessee at Memthis

    TitleAdjunct Professor
    InstitutionLouisiana State University Health Sciences Center
    DepartmentGenetics and Gene Therapy

    TitleAdjunct Professor
    InstitutionLouisiana State University Health Sciences Center
    DepartmentMicrobiology, Imunology, and Parasitology

    Collapse Affiliation 

    Collapse Biography 
    Collapse awards and honors
    2004McCaffrey/Norwood Professor of Pharmacy, Xavier University of Louisiana
    2012Fellow, American Association of Pharmaceutical Sciences (AAPS)

    Collapse Overview 
    Collapse overview
    Dr. Tarun Mandal is an Endowed Professor at Xavier University College of Pharmacy. He is also Adjunct Professor at the University of Tennessee at Memphis, University of Louisiana at Monroe, and the Louisiana State University Health Sciences Center. He is a Fellow of the American Association of Pharmaceutical Scientists. Tarun is the Director of the Center for Nanomedicine and Drug Delivery and Co-Director of the Louisiana Vaccine Center. He is a member of the Scientific Advisory Board of Autoimmune Technologies, LLC, New Orleans, LA. He is a reviewer of several study sections of NIH and DoD (US Army). He is a member of the USP Governance Committee. He is a member of the Editorial Board of (1) Clinical Medicine Reviews in Oncology; (2) Drug Development and Industrial Pharmacy; (3) Nanotechnology, Science and Applications; (4) Clinical Medicine: Oncology; (5) Journal of Biotechnology and Biomaterials; (6) Journal of Pharmacy and Pharmacology (’96-’03); (7) Pharmacy and Pharmacology Communications (’96-’03). His research interests include the development of novel pharmaceutical formulations using nanomedicine and novel drug delivery systems. During the past several years, he has been actively working on the development of numerous formulations, which include small molecules, proteins, peptides, DNA, siRNA. He has received several research grants from various state and federal agencies. He has published over 90 peer-reviewed original research papers. His research has resulted in a number of patented technologies in novel drug delivery.He received his B.S. degree in Pharmacy and M.S. and Ph.D. degrees in Pharmaceutics/Industrial Pharmacy.

    Collapse Research 
    Collapse research activities and funding
    R15DA013512     (MANDAL, TARUN K)Sep 30, 2002 - Aug 31, 2006
    SR Drug Delivery for the Treatment of Drug Abuse
    Role: Principal Investigator
    Collapse research resources
    This researcher has shared information about their research resources
    in the eagle-i Network. To update or add resource records, contact

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pramar YV, Mandal TK, Bostanian LA, Kader C, Morris TC, Graves RA. Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt. Int J Pharm Compd. 2021 Sep-Oct; 25(5):431-439. PMID: 34623970.
      Citations:    Fields:    Translation:Humans
    2. Pramar YV, Mandal TK, Bostanian LA, Le G, Morris TC, Graves RA. Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt. Int J Pharm Compd. 2021 Mar-Apr; 25(2):169-175. PMID: 33798117.
      Citations:    Fields:    Translation:Humans
    3. Bhattacharyya SK, Dule M, Paul R, Dash J, Anas M, Mandal TK, Das P, Das NC, Banerjee S. Carbon Dot Cross-Linked Gelatin Nanocomposite Hydrogel for pH-Sensing and pH-Responsive Drug Delivery. ACS Biomater Sci Eng. 2020 10 12; 6(10):5662-5674. PMID: 33320568.
    4. Pramar YV, Mandal TK, Bostanian LA, Le G, Morris TC, Graves RA. Physicochemical Stability of Compounded Allopurinol Suspensions in PCCA Base, SuspendIt. Int J Pharm Compd. 2020 Sep-Oct; 24(5):413-419. PMID: 32886640.
      Citations:    Fields:    Translation:Humans
    5. Chowdhury N, Chaudhry S, Hall N, Olverson G, Zhang QJ, Mandal T, Dash S, Kundu A. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment. AAPS PharmSciTech. 2020 Jul 21; 21(6):202. PMID: 32696338.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    6. Chandra S, Michael Nguyen H, Wiltz K, Hall N, Chaudhry S, Olverson G, Mandal T, Dash S, Kundu A. Aptamer-functionalized Hybrid Nanoparticles to Enhance the Delivery of Doxorubicin into Breast Cancer Cells by Silencing P-glycoprotein. J Cancer Treatment Diagn. 2020; 4(1):1-13. PMID: 32395707.
    7. Graves RA, Mandal TK, Bostanian LA, Nguyen AT, Swopes D, Morris TC, Pramar YV. Physicochemical Stability of Compounded Amlodipine Besylate Suspensions in PCCA Base, SuspendIt. Int J Pharm Compd. 2019 Nov-Dec; 23(6):519-527. PMID: 31751949.
      Citations:    Fields:    Translation:Humans
    8. Pramar YV, Mandal TK, Bostanian LA, Nguyen AT, Morris TC, Graves RA. Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base SuspendIt. Int J Pharm Compd. 2019 Mar-Apr; 23(2):157-162. PMID: 31085781.
      Citations:    Fields:    Translation:Humans
    9. Pramar YV, Mandal TK, Bostanian LA, Nguyen AT, Miller V, Morris TC, Graves RA. Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt. Int J Pharm Compd. 2019 Jan-Feb; 23(1):70-76. PMID: 30668538.
      Citations:    Fields:    Translation:Humans
    10. Graves RA, Phan KV, Bostanian LA, Mandal TK, Pramar YV. Physicochemical Stability of an Oral Suspension of Trimethoprim 20 mg/mL in Combination with Sulfadiazine 200 mg/mL in PCCA Base SuspendIt. Int J Pharm Compd. 2017 Sep-Oct; 21(5):430-435. PMID: 29216620.
      Citations:    Fields:    
    11. Graves R, Phan KV, Bostanian LA, Mandal TK, Pramar YV. Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt. Int J Pharm Compd. 2017 Jul-Aug; 21(4):334-338. PMID: 28719376.
      Citations:    Fields:    
    12. Kundu AK, Iyer SV, Chandra S, Adhikari AS, Iwakuma T, Mandal TK. Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma. PLoS One. 2017; 12(6):e0179168. PMID: 28636657.
      Citations:    Fields:    Translation:HumansCells
    13. Powell D, Chandra S, Dodson K, Shaheen F, Wiltz K, Ireland S, Syed M, Dash S, Wiese T, Mandal T, Kundu A. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J Pharm Biopharm. 2017 May; 114:108-118. PMID: 28131717.
      Citations: 16     Fields:    Translation:HumansCells
    14. Ledet GA, Biswas S, Kumar VP, Graves RA, Mitchner DM, Parker TM, Bostanian LA, Ghosh SP, Mandal TK. Development of Orally Administered ?-Tocotrienol (GT3) Nanoemulsion for Radioprotection. Int J Mol Sci. 2016 Dec 24; 18(1). PMID: 28029115.
      Citations: 2     Fields:    Translation:AnimalsPHPublic Health
    15. Pramar YV, Graves RA, Ledet GA, Phan KV, Bostanian LA, Mandal TK. Stability of Clindamycin Hydrochloride in PCCA Base SuspendIt. Int J Pharm Compd. 2016 Sep-Oct; 20(5):421-425. PMID: 28339377.
      Citations:    Fields:    
    16. Hossain A, Tauhid L, Davenport I, Huckaba T, Graves R, Mandal T, Muniruzzaman S, Ahmed SA, Bhattacharjee PS. LRP-1 Pathway Targeted Inhibition of Vascular Abnormalities in the Retina of Diabetic Mice. Curr Eye Res. 2017 04; 42(4):640-647. PMID: 27442082.
      Citations: 3     Fields:    Translation:AnimalsCells
    17. Hossain A, Heron D, Davenport I, Huckaba T, Graves R, Mandal T, Muniruzzaman S, Wang S, Bhattacharjee PS. Protective effects of bestatin in the retina of streptozotocin-induced diabetic mice. Exp Eye Res. 2016 08; 149:100-106. PMID: 27344955.
      Citations: 3     Fields:    Translation:Animals
    18. Das AK, Goswami S, Dutta G, Maity S, Mandal TK, Khanra K, Bhattacharyya N. A concentration dependent auto-relay-recognition by the same analyte: a dual fluorescence switch-on by hydrogen sulfide via Michael addition followed by reduction and staining for bio-activity. Org Biomol Chem. 2016 Jan 14; 14(2):570-576. PMID: 26510406.
      Citations: 2     Fields:    Translation:Cells
    19. Ledet G, Graves RA, Bostanian LA, Mandal TK. A second-generation inhaled insulin for diabetes mellitus. Am J Health Syst Pharm. 2015 Jul 15; 72(14):1181-7. PMID: 26150567.
      Citations: 1     Fields:    Translation:Humans
    20. Graves RA, Ledet GA, Nation CA, Pramar YV, Bostanian LA, Mandal TK. Effect of squalane on mebendazole-loaded Compritol® nanoparticles. J Biomater Sci Polym Ed. 2015; 26(13):868-80. PMID: 26062393.
      Citations:    Fields:    Translation:Cells
    21. Kumar R, Ledet G, Graves R, Datta D, Robinson S, Bansal GP, Mandal T, Kumar N. Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles. Pharm Res. 2015 Dec; 32(12):3827-36. PMID: 26113235.
      Citations: 7     Fields:    Translation:AnimalsPHPublic Health
    22. Graves RA, Ledet GA, Glotser EY, Mitchner DM, Bostanian LA, Mandal TK. Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide. Eur J Pharm Sci. 2015 Aug 30; 76:1-9. PMID: 25933716.
      Citations: 2     Fields:    Translation:HumansCells
    23. Ledet GA, Graves RA, Glotser EY, Mandal TK, Bostanian LA. Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles. Int J Pharm. 2015 Feb 20; 479(2):329-37. PMID: 25542987.
      Citations: 3     Fields:    Translation:HumansCells
    24. Graves RA, Ledet G, Nation CA, Showers PR, Pramar Y, Mandal T, Bostanian LA. An ultra-high performance chromatographic method for the determination of artemisinin. Drug Dev Ind Pharm. 2015 May; 41(5):819-24. PMID: 24738789.
      Citations:    Fields:    
    25. Paira TK, Saha A, Banerjee S, Das T, Das P, Jana NR, Mandal TK. Fluorescent amphiphilic PEG-peptide-PEG triblock conjugate micelles for cell imaging. Macromol Biosci. 2014 Jul; 14(7):929-35. PMID: 24687698.
      Citations:    Fields:    Translation:HumansCells
    26. Banerjee S, Maji T, Paira TK, Mandal TK. Amino-acid-based zwitterionic polymer and its Cu(II)-induced aggregation into nanostructures: a template for CuS and CuO nanoparticles. Macromol Rapid Commun. 2013 Sep; 34(18):1480-6. PMID: 23926055.
      Citations: 1     Fields:    
    27. Ledet G, Pamujula S, Walker V, Simon S, Graves R, Mandal TK. Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery. Drug Dev Ind Pharm. 2014 Mar; 40(3):370-9. PMID: 23600657.
      Citations: 4     Fields:    Translation:Animals
    28. Gopalakrishnan AM, Kundu AK, Mandal TK, Kumar N. Novel nanosomes for gene delivery to Plasmodium falciparum-infected red blood cells. Sci Rep. 2013; 3:1534. PMID: 23525038.
      Citations: 7     Fields:    Translation:AnimalsCells
    29. Bhattacharjee PS, Huq TS, Potter V, Young A, Davenport IR, Graves R, Mandal TK, Clement C, McFerrin HE, Muniruzzaman S, Ireland SK, Hill JM. High-glucose-induced endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein E. PLoS One. 2012; 7(12):e52152. PMID: 23284911.
      Citations: 10     Fields:    Translation:AnimalsCells
    30. Chandra PK, Kundu AK, Hazari S, Chandra S, Bao L, Ooms T, Morris GF, Wu T, Mandal TK, Dash S. Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther. 2012 Sep; 20(9):1724-36. PMID: 22617108.
      Citations: 29     Fields:    Translation:AnimalsCells
    31. Kundu AK, Chandra PK, Hazari S, Ledet G, Pramar YV, Dash S, Mandal TK. Stability of lyophilized siRNA nanosome formulations. Int J Pharm. 2012 Feb 28; 423(2):525-34. PMID: 22172291.
      Citations: 10     Fields:    Translation:HumansCells
    32. Pamujula S, Hazari S, Bolden G, Graves RA, Chinta DD, Dash S, Kishore V, Mandal TK. Cellular delivery of PEGylated PLGA nanoparticles. J Pharm Pharmacol. 2012 Jan; 64(1):61-7. PMID: 22150673.
      Citations: 16     Fields:    Translation:AnimalsCells
    33. Kundu AK, Chandra PK, Hazari S, Pramar YV, Dash S, Mandal TK. Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur J Pharm Biopharm. 2012 Feb; 80(2):257-67. PMID: 22119665.
      Citations: 11     Fields:    Translation:HumansCells
    34. Bhattacharjee PS, Huq TS, Mandal TK, Graves RA, Muniruzzaman S, Clement C, McFerrin HE, Hill JM. A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis. PLoS One. 2011 Jan 06; 6(1):e15905. PMID: 21253017.
      Citations: 15     Fields:    Translation:HumansAnimals
    35. Kundu AK, Hazari S, Chinta DD, Pramar YV, Dash S, Mandal TK. Development of nanosomes using high-pressure homogenization for gene therapy. J Pharm Pharmacol. 2010 Sep; 62(9):1103-11. PMID: 20796188.
      Citations: 4     Fields:    Translation:AnimalsCells
    36. Pamujula S, Hazari S, Bolden G, Graves RA, Chinta DM, Dash S, Kishore V, Mandal TK. Preparation and in-vitro/in-vivo evaluation of surface-modified poly (lactide-co-glycolide) fluorescent nanoparticles. J Pharm Pharmacol. 2010 Apr; 62(4):422-9. PMID: 20604830.
      Citations: 4     Fields:    Translation:AnimalsCells
    37. Devanga-Chinta D, Graves RA, Pamujula S, Mandal TK. Controlled release multiple layer coatings. Drug Dev Ind Pharm. 2010 Feb; 36(2):200-8. PMID: 20070184.
      Citations: 1     Fields:    
    38. Chinta DD, Graves RA, Pamujula S, Praetorius N, Bostanian LA, Mandal TK. Spray-dried chitosan as a direct compression tableting excipient. Drug Dev Ind Pharm. 2009 Jan; 35(1):43-8. PMID: 18622875.
      Citations: 2     Fields:    
    39. Pamujula S, Kishore V, Rider B, Agrawal KC, Mandal TK. Radioprotection in mice following oral administration of WR-1065/PLGA nanoparticles. Int J Radiat Biol. 2008 Nov; 84(11):900-8. PMID: 19016138.
      Citations: 5     Fields:    Translation:AnimalsCells
    40. Praetorius NP, Mandal TK. Alternate delivery route for amifostine as a radio-/chemo-protecting agent. J Pharm Pharmacol. 2008 Jul; 60(7):809-15. PMID: 18549666.
      Citations: 8     Fields:    Translation:HumansAnimals
    41. Graves RA, Poole D, Moiseyev R, Bostanian LA, Mandal TK. Encapsulation of indomethacin using coaxial ultrasonic atomization followed by solvent evaporation. Drug Dev Ind Pharm. 2008 Apr; 34(4):419-26. PMID: 18401784.
      Citations: 3     Fields:    
    42. Pamujula S, Graves RA, Moiseyev R, Bostanian LA, Kishore V, Mandal TK. Preparation of polylactide-co-glycolide and chitosan hybrid microcapsules of amifostine using coaxial ultrasonic atomizer with solvent evaporation. J Pharm Pharmacol. 2008 Mar; 60(3):283-9. PMID: 18284807.
      Citations: 3     Fields:    
    43. Graves RA, Freeman T, Mandal TK. In vitro dissolution method for evaluation of buprenorphine in situ gel formulation: a technical note. AAPS PharmSciTech. 2007 Aug 03; 8(3):E62. PMID: 17915812.
      Citations: 3     Fields:    
    44. Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul. 2007; 1(1):37-51. PMID: 19075873.
      Citations: 32     Fields:    Translation:Humans
    45. Graves RA, Freeman T, Pamajula S, Praetorius N, Moiseyev R, Mandal TK. Effect of co-solvents on the characteristics of enkephalin microcapsules. J Biomater Sci Polym Ed. 2006; 17(6):709-20. PMID: 16892730.
      Citations: 1     Fields:    Translation:PHPublic Health
    46. Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm. 2005 Jul 01; 62(13):1359-64. PMID: 15972377.
      Citations: 12     Fields:    Translation:Humans
    47. Pamujula S, Kishore V, Rider B, Fermin CD, Graves RA, Agrawal KC, Mandal TK. Radioprotection in mice following oral delivery of amifostine nanoparticles. Int J Radiat Biol. 2005 Mar; 81(3):251-7. PMID: 16019934.
      Citations: 7     Fields:    Translation:AnimalsCells
    48. Graves RA, Moiseyev R, Freeman T, Mandal TK. Effect of surfactant on the characteristics of biodegradable microcapsules. J Biomater Sci Polym Ed. 2005; 16(5):585-96. PMID: 16001718.
      Citations:    Fields:    Translation:AnimalsPHPublic Health
    49. Pamujula S, Graves RA, Freeman T, Srinivasan V, Bostanian LA, Kishore V, Mandal TK. Oral delivery of spray dried PLGA/amifostine nanoparticles. J Pharm Pharmacol. 2004 Sep; 56(9):1119-25. PMID: 15324480.
      Citations: 4     Fields:    Translation:Animals
    50. Pamujula S, Graves RA, Kishore V, Mandal TK. Preparation and in vitro characterization of amifostine biodegradable microcapsules. Eur J Pharm Biopharm. 2004 Mar; 57(2):213-8. PMID: 15018977.
      Citations: 1     Fields:    
    51. Graves RA, Pamujula S, Moiseyev R, Freeman T, Bostanian LA, Mandal TK. Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of pentamidine microcapsules. Int J Pharm. 2004 Feb 11; 270(1-2):251-62. PMID: 14726140.
      Citations: 10     Fields:    
    52. Mandal TK, Bostanian LA, Graves RA, Chapman SR. Poly(D,L-lactide-co-glycolide) encapsulated poly(vinyl alcohol) hydrogel as a drug delivery system. Pharm Res. 2002 Nov; 19(11):1713-9. PMID: 12458678.
      Citations: 4     Fields:    
    53. Mandal TK, Bostanian LA, Graves RA, Chapman SR, Womack I. Development of biodegradable microcapsules as carrier for oral controlled delivery of amifostine. Drug Dev Ind Pharm. 2002 Mar; 28(3):339-44. PMID: 12026226.
      Citations: 4     Fields:    
    54. Mandal TK, Bostanian LA, Graves RA, Chapman SR, Idodo TU. Porous biodegradable microparticles for delivery of pentamidine. Eur J Pharm Biopharm. 2001 Jul; 52(1):91-6. PMID: 11438428.
      Citations: 1     Fields:    Translation:PHPublic Health
    55. Mandal TK. Swelling-controlled release system for the vaginal delivery of miconazole. Eur J Pharm Biopharm. 2000 Nov; 50(3):337-43. PMID: 11072189.
      Citations: 7     Fields:    Translation:Cells
    56. Mandal TK. American Association of Pharmaceutical Scientists--annual meeting and exposition. 14-18 November 1999, New Orleans, LA, USA. IDrugs. 2000 Feb; 3(2):147. PMID: 16107924.
      Citations:    Fields:    
    57. Mandal TK, Bostanian LA. Effect of peptide loading and surfactant concentration on the characteristics of physically crosslinked hydrogel. Pharm Dev Technol. 2000; 5(4):555-60. PMID: 11109254.
      Citations: 1     Fields:    
    58. Mandal TK. Development of biodegradable drug delivery system to treat addiction. Drug Dev Ind Pharm. 1999 Jun; 25(6):773-9. PMID: 10349563.
      Citations: 3     Fields:    Translation:Humans
    59. Mandal TK. American College of Cardiology--48th annual scientific session. 7-10 March 1999, New Orleans, LA, USA. IDrugs. 1999 May; 2(5):393. PMID: 16155835.
      Citations:    Fields:    
    60. Mandal TK. Effect of solvent on the characteristics of pentamidine loaded microcapsule. J Biomater Sci Polym Ed. 1999; 10(1):1-17. PMID: 10091919.
      Citations: 4     Fields:    Translation:HumansAnimals
    61. Mandal TK. Evaluation of a novel phase separation technique for the encapsulation of water-soluble drugs in biodegradable polymer. Drug Dev Ind Pharm. 1998 Jul; 24(7):623-9. PMID: 9876506.
      Citations:    Fields:    Translation:PHPublic Health
    62. Mandal TK, Shekleton M, Onyebueke E, Washington L, Penson T. Effect of formulation and processing factors on the characteristics of biodegradable microcapsules of zidovudine. J Microencapsul. 1996 Sep-Oct; 13(5):545-57. PMID: 8864992.
      Citations: 2     Fields:    Translation:PHPublic Health
    63. Mandal TK. Effect of tablet integrity on the dissolution rate of sustained-release preparations. J Clin Pharm Ther. 1996 Jun; 21(3):155-7. PMID: 8873848.
      Citations: 3     Fields:    
    64. Mandal TK, Lopez-Anaya A, Onyebueke E, Shekleton M. Preparation of biodegradable microcapsules containing zidovudine (AZT) using solvent evaporation technique. J Microencapsul. 1996 May-Jun; 13(3):257-67. PMID: 8860682.
      Citations: 4     Fields:    Translation:PHPublic Health
    Mandal's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (284)
    Co-Authors (9)
    Similar People (60)
    Same Department Expand Description
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support